US78397T1034 – SPAC Feed

Nasdaq:SABS
Nasdaq:SABSW
US78397T1034

March 17, 2026

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type…

By sf-admin